4/3
06:01 am
derm
Journey Medical Co. (NASDAQ: DERM) was given a new $10.50 price target on by analysts at Industrial Alliance Securities.
Medium
Report
Journey Medical Co. (NASDAQ: DERM) was given a new $10.50 price target on by analysts at Industrial Alliance Securities.
4/1
04:01 pm
derm
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
Medium
Report
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
3/28
08:03 am
derm
Journey Medical Co. (NASDAQ: DERM) had its "buy" rating re-affirmed by analysts at Alliance Global Partners.
Low
Report
Journey Medical Co. (NASDAQ: DERM) had its "buy" rating re-affirmed by analysts at Alliance Global Partners.
3/26
04:01 pm
derm
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
Medium
Report
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
3/24
08:30 am
derm
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
High
Report
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
3/19
04:01 pm
derm
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
Medium
Report
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
3/12
08:30 am
derm
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
Low
Report
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
3/5
04:01 pm
derm
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
Medium
Report
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
3/4
06:13 pm
derm
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida [Yahoo! Finance]
Medium
Report
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida [Yahoo! Finance]
3/4
04:01 pm
derm
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
Medium
Report
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
1/24
09:16 am
derm
Minot Light Capital's Largest Performance Detractor in Q4: Journey Medical (DERM) [Yahoo! Finance]
Medium
Report
Minot Light Capital's Largest Performance Detractor in Q4: Journey Medical (DERM) [Yahoo! Finance]
1/23
09:03 am
derm
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea [Yahoo! Finance]
Medium
Report
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea [Yahoo! Finance]
1/23
08:30 am
derm
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
Low
Report
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea